RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
Regulatory Focus™ > News Articles > 2020 > 4 > Recon: Blackstone invests $2B in Alnylam; Promising data prompts AstraZeneca to unblind Tagrisso stu

Recon: Blackstone invests $2B in Alnylam; Promising data prompts AstraZeneca to unblind Tagrisso study early

Posted 13 April 2020 | By Michael Mezher 

Recon: Blackstone invests $2B in Alnylam; Promising data prompts AstraZeneca to unblind Tagrisso study early

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
 
In Focus: US
  • Blackstone Invests $2 Billion in Alnylam Pharmaceuticals (WSJ) (Reuters) (Endpoints) (Press)
  • Early Experience With Remdesivir To Treat Severe COVID-19 Published (NPR) (Bloomberg) (WSJ) (Financial Times) (Reuters) (NEJM)
  • US coronavirus outbreak could peak this week, CDC director says (Reuters)
  • US still falling short on accurate testing, FDA chief says (Politico)
  • US close to coronavirus peak, but we have to take it 'day by day': FDA commissioner (ABC)
  • Fears of ‘Wild West’ as COVID-19 blood tests hit the market (AP)
  • Coronavirus Tests Are Being Fast-Tracked by the FDA, but It’s Unclear How Accurate They Are. (ProPublica 1, 2)
  • Large-scale COVID-19 antibody testing study launched in California (NBC)
  • South Korea set to ship coronavirus testing kits to US (Reuters)
  • Drugmaker Eli Lilly starts clinical testing of therapies for COVID-19 (Reuters)
  • He Could Have Seen What Was Coming: Behind Trump’s Failure on the Virus (NYTimes)
  • Trump inches toward open war with his health department (Politico)
  • A key ingredient that compound pharmacies need for hydroxychloroquine skyrockets in price (STAT)
  • AstraZeneca Wins First FDA Drug Nod for NF1 (Xconomy) (Endpoints) (FDA) (Press)
  • J&J Drops $400M Deal For Takeda's Surgical Patch (Law360-$) (MedtechDive)
  • Damage From OxyContin Continues to Be Revealed (NYTimes)
In Focus: International
  • France Reports Heart Incidents Linked to Drug Promoted by Trump (Bloomberg)
  • Small Chloroquine Study Halted Over Risk of Fatal Heart Complications (NYTimes)
  • Amneal running out of hydroxychloroquine raw material due to Finnish restrictions (Reuters)
  • UK cancels order for simple ventilators, needs more complex ones: source (Reuters)
  • AstraZeneca's top-selling cancer drug sees early unblinding in key trial (Reuters) (STAT)
  • WHO: 70 coronavirus vaccines are in development globally (The Hill)
  • Israeli defence firm Elbit Systems to produce ventilators (Reuters)
  • WHO is investigating reports of recovered COVID patients testing positive again (Reuters)
  • To Belgrade and beyond: Beijing exports China model of virus management (Reuters)
  • Ebola patient dies in Congo, first case in 50 days (Reuters)
  • Congo records second Ebola death in days: WHO (Reuters)
Coronavirus Outbreak
  • Developing Covid-19 Vaccines at Pandemic Speed (NEJM)
  • The Employer Will Test You Now (WSJ)
  • From Clinton to Trump, 20 years of boom and mostly bust in prepping for pandemics (NBC)
  • Apple and Google Team Up to ‘Contact Trace’ the Coronavirus (NYTimes)
  • New FDA coronavirus guidelines focus on protecting food service workers (Axios)
  • ‘We need an army’: Hiring of coronavirus trackers seen as key to curbing disease spread (STAT)
  • Startups spar with FDA over what constitutes a home coronavirus test (STAT)
  • Sewage analysis suggests a New England metro area with fewer than 500 COVID-19 cases may have exponentially more (ABC)
  • New FDA Policy Significantly Limits Serological Testing (FDA Law Blog)
  • Evaluation of nine commercial SARS-CoV-2 immunoassays (medRxiv)
  • Omeprazole As An Additive For Coronavirus Therapy (In the Pipeline)
  • Scientist Kizzmekia Corbett leads the way on COVID-19 vaccine trials with dedication and humor (NBC)
  • The White House Pushed FEMA To Give its Biggest Coronavirus Contract to a Company That Never Had to Bid (ProPublica)
  • 'Elbow to elbow:' North America meat plant workers fall ill, walk off jobs (Reuters)
  • How a Premier US Drug Company Became a Virus ‘Super Spreader’ (NYTimes)
  • Why Are Some People So Much More Infectious Than Others? (NYTimes)
  • Man Charged in Scheme to Sell 125 Million Nonexistent Masks (NYTimes)
  • How false hope spread about hydroxychloroquine to treat covid-19 — and the consequences that followed (Washington Post)
  • COVID-19 Patients Given Unproven Drug In Texas Nursing Home In 'Disconcerting' Move (NPR)
  • Inside first clinical trial testing malaria drug as coronavirus treatment (NBC)
  • China's new coronavirus cases rise to near six-week high (Reuters)
  • Iran records 4,585 coronavirus deaths as restrictions eased (Reuters)
  • UK coronavirus death toll nears 10,000 as minister says PM Johnson must rest (Reuters)
  • Some Spaniards head back to work in face masks as country loosens lockdown (Reuters)
  • Master protocols emerge as a critical clinical tool against COVID-19 (BioCentury)
  • Hope Biosciences Receives Second FDA Clearance for a Phase II Clinical Trial for Protection Against COVID-19 (Press)
  • FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome (Press)
  • Celltrion plans July COVID-19 trial, advances 'super antibody' (Fierce)
Pharmaceuticals & Biotechnology
  • Coronavirus Pandemic Brings Hundreds Of US Clinical Trials To A Halt (NPR)
  • Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals (STAT)
  • Lost opportunities from FDA, NIH inaction when sponsors fail to report clinical trial results (STAT)
  • Insurers, drug makers, and patient advocates blast two Trump proposals to drive down drug prices (STAT)
  • Q&A: Analyst-turned biotech exec-turned analyst reads the biotech Q1 tea leaves (Endpoints)
  • Aslan's Dupixent rival test put on hold amid COVID-19, but delays shouldn't hit readout (Fierce)
  • Notice of Change to the Application Due Date and correct Section II Award Information - Award Budget for RFA-FD-20-030 "Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (FDA)
Medical Devices
  • Abbott lands CE mark for tricuspid sibling of MitraClip (MedtechDive)
US: Assorted & Government
  • 3M claims distributor tried to sell masks to NYC officials for six times the price (The Hill)
  • Battle over drugs for Nevada execution ends with no decision (News Las Vegas)
  • Federal Government’s Battle To Reassert Control of FCA Filings Ostensibly in its Name (Drug & Device Law)
  • Impact of COVID-19 Pandemic on Patent Offices and Federal Courts – April 12 UPDATE (Patent Docs)
  • CVC Reply No. 1 to Broad's Opposition No. 1 to CVC's Motion No. 1 to Be Accorded Benefit of Priority (Patent Docs)
  • Request for Information on Vaping Products Associated With Lung Injuries; Extension of Comment Period (FDA)
Australia
  • Expedited recall system for faulty or unauthorised COVID-19 devices (TGA)
Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
 
Need to contact the editor of Regulatory Reconnaissance? Email us at news@raps.org.
 
A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe